Merck & Co., Inc.

Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R) [Press Release]
PRNewswire | 2 days 9 hours 35 minutes ago
Merck Receives CHMP Positive Opinion for New...Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc. today announced the Committee for Medicinal...Romanelli,+1-908-423-5088, all of Merck & Co., Inc.

Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol [Press Release]
Business Wire | 7 days 5 hours 30 minutes ago
At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin), and issued the following comment in response to misinterpretation of results from a small 200-patient imaging study called ARBITER 6.

Higher Dose of Merck s COZAAR (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study [Press Release]
Business Wire | 5 days 15 hours 42 minutes ago
In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR. The Merck-sponsored study compared the safety and efficacy of two doses of COZAAR® in patients with chronic heart failure and reduced cardiac function (left ventricular ejection fraction) who were intolerant of angiotensin-converting enzym...

FDA Approves GARDASIL for Use in Boys and Young Men [Press Release]
Business Wire | 37 days 11 hours 22 minutes ago
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recom...

Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc. [Press Release]
Business Wire | 3 days 15 hours 12 minutes ago
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

New Merck Begins Operations [Press Release]
Business Wire | 18 days 15 hours 42 minutes ago
Merck & Co., Inc. (NYSE: MRK) today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

Merck and Schering-Plough to Complete Merger Today [Press Release]
Business Wire | 19 days 11 hours 59 minutes ago
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will begin combined operations tomorrow, November 4, 2009. As previously announced, Schering-Plough will change its name to Merck and its common stock will trade under the ticker symbol “MRK” on the New York Stock Exchange.

Critical Alerts For Merck, Monsanto, Urban Outfitters, Petrohawk Energy, and Vistaprint Released By Seven Summits Research [Press Release]
PRNewswire | 3 days 8 hours 11 minutes ago
Critical Alerts For Merck, Monsanto, Urban Outfitters, Petrohawk Energy, and Vistaprint... Today's PriceWatch Alerts cover the following stocks: Merck & Co. Inc. , Monsanto Co. , Urban Outfitters Inc. , Petrohawk Energy Corporation...

Fitch Downgrades Merck and Upgrades Schering-Plough to 'A+' Following Merger; Outlook Stable [Press Release]
Business Wire | 18 days 7 hours 53 minutes ago
As a result of the completed merger between Merck & Co., Inc. (Merck) and Schering-Plough Corp. (Schering-Plough) yesterday, Fitch Ratings has downgraded Merck's Issuer Default Rating (IDR) to 'A+' from 'AA-' and upgraded Schering-Plough's IDR to 'A+' from 'BBB+'. Simultaneously, Fitch downgraded Merck's senior unsecured debt and bank loan ratings to 'A+' from 'AA-' and downgraded the short-term IDR and commercial paper rating to 'F1' from 'F1+'. The ratings were also removed from Rating Watc...

Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc. [Press Release]
PRNewswire | 20 days 12 hours 52 minutes ago
COPENHAGEN, November 2 /PRNewswire/ -- Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ.

River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries [Press Release]
PRNewswire | 1 day 2 hours 57 minutes ago
...PAHO (the American regional office of the World Health Organization), and the Bill & Melinda Gates Foundation. Merck & Co., Inc. contributes greatly to the program's achievements by donating supplies of Mectizan for as long as is necessary...

Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger [Press Release]
Business Wire | 24 days 6 hours 47 minutes ago
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the U.S. Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger.